Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIQ

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.


TSXV:IPCI.H - Post by User

Comment by Nogah3on Jan 16, 2020 9:24am
146 Views
Post# 30559633

RE:RE:Pipeline

RE:RE:PipelineRespectfully Kamooz, I think you missed the point. If oxycodone is going to be approved then that would open a $1.3 Bil market. Well IPCI just recently signed three of its FDA approved drugs that are also for the same market size (>$1.2bil). This will be reflected in Q4. Again remember that the oxycodone can be approved at later date (it is not scrapped). Another point I didn't mention in the last post is if you look at the MD&A you will notice that the company is not relying soley on USA market and is already in talks with Pharma in Vietnam, Malaysia, and Philipines to their products. Finalization of these agreements can happen at anytime. Unfortunately, for stockholders who don't appreciate how such businesses work, they will start panicing and will think they need to sell at any price. The company has huge potential through several drugs and has already shown it can enter the market through 4 FDA approved drugs. I hope this helps in deciding whether to sell the company at a quater of its fair value.
<< Previous
Bullboard Posts
Next >>